Integral Diagnostics Ltd

As of June 30, 2026, INTEGRAL DIAGNOSTICS LTD carries a market capitalization of 971.48M, placing it among publicly traded companies globally. Its enterprise value stands at 1.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

INTEGRAL DIAGNOSTICS LTD's next confirmed earnings release is scheduled for February 16, 2027.

As of June 30, 2026, INTEGRAL DIAGNOSTICS LTD has 371.86M shares outstanding.

As of June 30, 2026, INTEGRAL DIAGNOSTICS LTD trades at a trailing price-to-earnings ratio of 64.07. The price-to-sales ratio is 1.78, and the price-to-book ratio stands at 2.08.

As of June 30, 2026, INTEGRAL DIAGNOSTICS LTD trades at an EV/EBITDA multiple of 13.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 28.57 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.35B versus a market cap of 971.48M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, INTEGRAL DIAGNOSTICS LTD maintains a current ratio of 0.67, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 87.62, indicating elevated leverage, while an interest coverage ratio of 7.00 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, INTEGRAL DIAGNOSTICS LTD posted a return on equity (ROE) of 3.20, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.66 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.80, useful for judging operating efficiency across full business cycles. The company generates approximately 178,995.44 in revenue per employee across its workforce of 3,049.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.10 indicates how many times INTEGRAL DIAGNOSTICS LTD sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, INTEGRAL DIAGNOSTICS LTD recorded 6.97M in income tax expense. That works out to an effective tax rate of 31.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.22M, leaving 15.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on July 2, 2026, INTEGRAL DIAGNOSTICS LTD's stock has declined approximately 52.38% over the past 52 weeks.

Over the twelve months ended June 30, 2026, INTEGRAL DIAGNOSTICS LTD generated 545.76M in revenue and converted that into 15.18M in net income, yielding earnings per share of 0.04. EBITDA reached 98.66M, while operating income came in at 47.37M.

As of June 30, 2026, INTEGRAL DIAGNOSTICS LTD holds 35.49M in cash and equivalents against 413.22M in total debt, resulting in a net debt position of 201.04M. Total book value stands at 467.80M, with working capital of -34.08M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, INTEGRAL DIAGNOSTICS LTD posted a gross margin of 95.44, reflecting its pricing power and cost economics. The operating margin of 8.68 and net profit margin of 2.78 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, INTEGRAL DIAGNOSTICS LTD paid dividends of 0.05 per share. The dividend payout ratio of 117.07 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to INTEGRAL DIAGNOSTICS LTD shareholders.

INTEGRAL DIAGNOSTICS LTD's most recent stock split took place on February 25, 2022.

As of June 30, 2026, INTEGRAL DIAGNOSTICS LTD has an Altman Z-Score of 2.67, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.